US › Healthcare

Genmab AS (GMAB)

US · Healthcare · Biotechnology

$29.02+1.19%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$899.3M

Revenue YoY

+754.6%

Net profit

$53.2M

Profit YoY

+85.4%

EPS

$0.13

EPS estimate

$0.19

Net margin

5.9%

EPS came in at 0.13 against a street estimate of 0.19 — a miss of 31.6%.

Key statistics

Market cap

$17.72B

P/E

21.9

Forward P/E

16.8

P/B

3.12

Book value

$9.26

EPS (TTM)

$1.32

52-week high

$35.43

52-week low

$21.00

50-day MA

$27.04

200-day MA

$29.06

Beta

0.69

Analyst view

Analysts rate Genmab AS a buy (5 buy, 4 hold, 0 sell out of 9) with an average price target of $37.96.

Shareholding

Institutions

13.55%

Largest institutional holders

Fund	Stake
Orbis Allan Gray Ltd	2.11%
AllianceBernstein L.P.	1.56%
Paradigm Biocapital Advisors LP	1.30%
Arrowstreet Capital Limited Partnership	0.81%
BlackRock Inc	0.74%
Renaissance Technologies Corp	0.72%
Deep Track Capital, LP	0.60%
Harding Loevner L.P.	0.53%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Genmab AS — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.